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Abstract
Background: The IGF receptor type 1 (IGF-1R) pathway is frequently deregulated in human tumors and has become a target
of interest for anti-cancer therapy.
Methodology/Principal Findings: We used a panel of 22 non-small cell lung cancer (NSCLC) cell lines to investigate
predictive biomarkers of response to R1507, a fully-humanized anti-IGF-1R monoclonal antibody (Ab; Roche). 5 lines were
moderately sensitive (25–50% growth inhibition) to R1507 alone. While levels of phospho-IGF-1R did not correlate with drug
sensitivity, 4 out of 5 sensitive lines displayed high levels of total IGF-1R versus 1 out of 17 resistant lines (p=0.003, Fisher’s
Exact). Sensitive lines also harbored higher copy numbers of IGF-1R as assessed by independent SNP array analysis. Addition
of erlotinib or paclitaxel to R1507 led to further growth inhibition in sensitive but not resistant lines. In one EGFR mutant
lung adenocarcinoma cell line (11–18), R1507 and erlotinib co-treatment induced apoptosis, whereas treatment with either
drug alone induced only cell cycle arrest. Apoptosis was mediated, in part, by the survival-related AKT pathway.
Additionally, immunohistochemical (IHC) staining of total IGF-1R with an anti-total IGF-1R Ab (G11;Ventana) was performed
on tissue microarrays (TMAs) containing 270 independent NSCLC tumor samples. Staining intensity was scored on a scale of
0t o3 +. 39.3% of tumors showed medium to high IGF-1R IHC staining (scores of 2+ or 3+, respectively), while 16.7% had
scores of 3+.
Conclusions/Significance: In NSCLC cell lines, high levels of total IGF-1R are associated with moderate sensitivity to R1507.
These results suggest a possible enrichment strategy for clinical trials with anti-IGF-1R therapy.
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Introduction
Lung cancer is the leading cause of cancer-related death in the
United States and worldwide [1]. Lung cancers are currently
classified into two major groups depending on the morphologic
pathological appearance: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC) [2].The latter is comprised of
three different subtypes: adenocarcinoma, squamous cell carcino-
ma, and large cell carcinoma. Despite recent advances in
treatments for the disease, the overall 5-year survival in the
United States remains only 15% [3], highlighting the need for
novel treatment strategies.
One emerging approach involves targeting of the type I insulin-
like growth factor receptor (IGF-1R) pathway [4,5,6]. This axis
plays animportantroleinmammalian cell growthanddevelopment
[7]. The main components include the IGF-1R and its highly
structurally conserved family member, the insulin receptor (IR).
Both receptors consist of two half-receptors, each comprising one
extracellular alpha-subunit and one transmembrane beta-subunit
that possess tyrosine kinase activity [8]. IGF-1Rs and IRs can
homodimerize or form IGF-1R/IR heterodimers. While the IR is
activated by insulin, IGF-1R is activated by its ligands, IGF-1 and
IGF-II. The availability of IGF-1R ligands is additionally regulated
by at least six high-affinity IGF-binding proteins (IGFBP1-6) which
broadly function to inhibit IGF bioactivity.
The IGF-1R pathway appears to play important roles in
tumorigenesis, metastasis, and resistance to existing forms of anti-
cancer therapy [7,8]. In lung cancer, elevated plasma levels of
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[9]. Conversely, high plasma levels of IGFBP3 have been
associated with reduced risk [10]. High IGF-1R expression is
associated with poor survival in surgically treated NSCLC patients
[11]. In a recent randomized phase II trial involving patients with
stage IIIB, IV, or recurrent, treatment-naı ¨ve NSCLC, addition of
an anti-IGF-1R antibody (CP-751,871; Pfizer) to standard
chemotherapy (paclitaxel and carboplatin) led to a 46% objective
response rate versus a 32% rate in patients receiving chemother-
apy alone [12]. A phase III trial is underway.
Here, we sought to identify molecular biomarkers in NSCLC
that may predict for benefit from anti-IGF-1R directed therapy.
Specifically, we analyzed parameters that may be associated with
sensitivity of 22 NSCLC lines to R1507 (RO4858696; Roche), a
fully humanized IgG1 monoclonal antibody directed against the
extracellular portion of IGF-1R. It binds with high selectivity to
the extracellular domain of IGF-1R (and not to IR), leading to
displacement of IGF-1 binding and loss of protein at the cell
surface due to receptor internalization and degradation. After
identifying one potential biomarker, we analyzed signaling
properties affected by anti-IGF-1R treatment in various cell lines
and evaluated expression status of the biomarker in 270 NSCLC
patient samples.
Methods
Cell culture
The human lung adenocarcinoma cell lines H3255, PC-9 and
H1975 were described previously [13]. 11–18 was kindly provided
by Koichi Hagiwara. A549, HCC827, H2170, H520, H661,
H226, SK-MES-1, SW900, H1703, H460 were obtained from
ATCC (Manassas, VA). HCC15, H322, H322M, HCC2450,
HCC95, HCC2279, HCC2935, and HCC4006 were kindly
provided by Adi Gazdar (University of Texas Southwestern
Medical Center, Dallas). Cells except SK-MES-1 and SW900
were maintained in RPMI 1640 (ATCC) supplemented with 10%
fetal bovine serum and Pen-Strep Solution (both from Gemini Bio-
Products, West Sacramento, CA) in a humidified incubator with
5% CO2 at 37uC. SK-MES-1 cells were grown in Eagle’s
Minimum Essential medium (ATCC) supplemented with 10%
fetal bovine serum and Pen-Strep Solution. SW900 cells were
cultured in Leibovitz’s L-15 Medium (ATCC) supplemented with
10% fetal bovine serum and Pen-Strep Solution (both from
Gemini Bio-Products, West Sacramento, CA).
Reagents
Anti-IGF-1R antibody R1507 was kindly provided by Hoff-
mann-La Roche Inc (Nutley, NJ). Erlotinib was synthesized by the
Organic Synthesis Core Facility at Memorial Sloan-Kettering
Cancer Center. Paclitaxel was purchased from EMD Biosciences
(La Jolla, CA). The VybrantH Apoptosis Assay Kit #2 was from
Invitrogen (Carlsbad, CA). The phospho-receptor tyrosine kinase
(RTK) array kit, human IGF-1R ELISA kit, human phospho-IGF-
1R ELISA kit, and recombinant human IGF-1 were from R&D
Systems (Minneapolis, MN). Recombinant human EGF was from
Cell Signaling Technology (Danvers, MA).
Antibodies
Anti- pERK(Thr202/Tyr204), -ERK, -pAKT (Ser473), -AKT,
-pEGFR (Tyr1092), -pIGF-1Rb (Tyr 1135/1136) and -IGF-1Rb
antibodies, and HRP-conjugated secondary antibodies were
purchased from Cell Signaling Technology (Danvers, MA). (Note
that EGFR has two numbering systems. The first denotes the
initiating methionine in the signal sequence as amino acid 224.
The second denotes the methionine as amino acid +1. Commer-
cial antibodies, such as the Y1068-specific anti-phospho-EGFR,
use the first nomenclature. In the second nomenclature, which we
use here, Y1068 is Y1092.) Anti-total EGFR antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA).
Growth inhibition and apoptosis assays
Cells were seeded in 96-well plates at a density of 5,000 cells in
triplicate and treated with different concentrations of drugs on the
following day. The growth status of drug-treated cells was measured
at 72 hours post treatment using CellTiter Blue Reagent (Promega,
Madison, WI). Annexin V/PI apoptosis assays (Invitrogen) were
performed according to manufacturer’s instructions.
Immunoblotting
Cells were scraped from 10 cm petri dishes, washed twice with
PBS, and then incubated in RIPA lysis buffer containing protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), 40 mM
sodium fluoride and 1 mM sodium orthovanadate for 30 min.
The supernatants were subjected to SDS-polyacrylamide gel
electrophoresis (Invitrogen) followed by blotting with indicated
antibodies. Signals were detected by SupersignalH West Pico
Luminol/Enhancer Solution (Pierce Biotechnology, Rockford, IL).
ELISAs
Phospho- and total IGF-1R ELISAs were performed according
to manufacturer’s instructions (R&D Systems). For phospho-IGF-
1R ELISAs, 100 mg of total protein was used for each cell line. For
total IGF-1R ELISAs, 25 mg of total protein was used for most of
the cell lines. For cells lines with high IGF-1R expression (A549,
H322, H322M, 11–18, HCC95), only 5 mg of total protein was
used.
Phospho-RTK array
Phospho-RTK array was performed according to manufactur-
er’s instructions (R&D Systems). 300 mg of total protein was used
for each membrane.
Gene silencing by siRNA
11–18 cells were seed into 6-well plates at a density of
1.25610
5 cells/well. 24 hour later, cells were transfected with
siRNAs against GFP (High Throughput Screening Core Facility,
Memorial Sloan-Kettering Cancer Center), human IGF-1R or
human GAPDH (ON-TARGETplus SMARTpool, Dharmacon Inc.,
Chicago, IL) using DharmaFECT 1 transfection reagent as per
manufacturer’s instruction. Cells were harvested 48 hours after
transfection to analyze the level of protein expression by
immunoblotting analysis.
Immunohistochemistry (IHC)
Tissue microarrays (TMAs) were constructed using a fully
automated Beecher Instrument, ATA-27, with triplicate cores for
each case. Use of human tissues was approved with an institutional
waiver and by the human bioutilization committee. The study
cohort was comprised of NSCLCs consecutively ascertained at the
Memorial Sloan-Kettering Cancer Center (MSKCC) between
1999 and 2006. All biopsies were evaluated at MSKCC, and the
histologic diagnosis was based on hematoxylin-eosin staining.
TMAs were stained as per manufacturer’s instructions on the
Ventana Benchmark XT with the anti-IGF-1R rabbit monoclonal
antibody (G11; Ventana-Roche, Tuscon, AZ) directed against the
C-terminus of the beta chain. Images were obtained with the
Olympus DP20 Camera (Center Valley, PA) and taken with the
Anti-IGF-1R Therapy in NSCLC
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was performed using Adobe Photoshop 7.0 and DP20 software.
Cores were scored as follows: 0, no staining; 1, weak focal staining;
2, moderate staining; 3, strong staining with at least 10% of the
core showing complete membranous staining. Cores were assigned
1 score and read by 2 pathologists (JTF and MA).
For IHC of cell lines, 30 million cells per line were fixed in 4%
paraformaldehyde for 10 minutes, washed with 70% ethanol, and
spun down into pellets. The pellets were kept in 70% ethanol in
4uC until they were paraffin-embedded and then processed as
above.
SNP array
As part of a larger effort to characterize the genomes of
NSCLC, some authors (MP and RKT) analyzed 84 NSCLC cell
lines for chromosomal gene copy number alterations, gene
mutations, transcriptional changes and drug response. The
detailed description of this collection was published elsewhere
[14]. Copy number analysis was performed using 250 K StyI
Affymetrix SNP-arrays; data was analyzed using GenePattern
software (www.broad.mit.edu/cancer/software/genepattern/) and
R (http://www.r-project.org/). All data is MIAME compliant and
the raw data has been deposited in a MIAME compliant database
GEO (accession number GSE17247).
Mutational profiling of IGF-1R
The full-length cDNAs of IGF-1R obtained from R1507
sensitive lines (11–18, HCC15, H322, H322 and A549) and select
resistant lines (HCC95 and H1975) were sequenced via direct
Sanger-based sequencing of PCR fragments amplified with M13
tagged primer pairs (Table S1).
Results
NSCLC cell lines display differential sensitivities to single
agent R1507
R1507 (RO4858696) is a fully human IgG1 monoclonal
antibody directed against the extracellular (alpha chain subunit)
portion of the human IGF-1R. To confirm that R1507 binds
selectively to human IGF-1R, cell lysates from two cell lines
(H3255 and 11–18) were immunoprecipitated with R1507 and
then immunoblotted with a commercial antibody that recognizes
the beta chain subunit of IGF-1R. Compared to whole cell
extracts, immunoprecipitation with R1507 readily enriched
detection of IGF-1R in lysates from both lines (Figure S1).
We next established the sensitivity to R1507 of 22 NSCLC cell
lines. These included 12 adenocarcinomas, 9 squamous cell
carcinomas and 1 large cell carcinoma, all examined for known
EGFR/KRAS/NRAS/HRAS/PI3K mutations [15] (Figure 1).
Sensitivity was assessed using a growth inhibition assay that
measures a colorimetric signal produced by conversion of
resazurin to resorufin, which is directly proportional to the
numbers of viable cells. Lines were grown in 10% serum for 72 h
in different concentrations (0.1–25 mg/ml) of R1507. None of the
lines displayed high sensitivity (Figure S2). Thus, we could not
calculate the concentration of drug needed to inhibit growth by
50% (GI50) for each line. Instead, we compared the maximum
levels of growth inhibition observed across all cell lines that were
Figure 1. NSCLC cell lines display differential sensitivity to single agent R1507. Various cell lines were treated with R1507 for 72 hours, and
cell growth inhibition was measured using CellTiter Blue reagents. The maximum growth inhibition obtained at an R1507 concentration of 25 mg/ml
was plotted for each cell line. Data represent the mean 6 standard deviation of triplicates.
doi:10.1371/journal.pone.0007273.g001
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Among the 22 cell lines, 5 (11–18, A549, HCC15, H322, and
H322M) displayed 25–50% growth inhibition, whereas the
remaining 17 cell lines showed less than 20% inhibition. We
chose to define the former lines as ‘‘sensitive’’, while the latter lines
were deemed ‘‘resistant’’. There was no obvious correlation
between R1507 sensitivity and lung cancer histology or mutation
status.
Phospho-IGF-1R levels do not correlate with R1507
sensitivity
To assess whether specific activated receptor tyrosine kinases
might correlate with R1507 sensitivity, we incubated lysates from
sensitive and resistant lines with a human phospho-RTK array
containing antibodies that capture 42 different phosphorylated
RTKs. Cell lines were grown in the absence or presence of serum.
Lysates from 11–18 cells (the most sensitive line to R1507 in
Figure 1) contained high levels of phospho-IGF-1R (data not
shown). However, none of the remaining four sensitive lines did.
We also did not detect any obvious correlation between sensitivity
and activated RTKs (data not shown).
To achieve a more quantitative assessment of the levels of
phosphorylated IGF-1R in the various cells, we applied cell lysates
from 16 of the 22 lines to a sandwich ELISA assay, designed with
an antibody that specifically recognizes IGF-1R and does not cross
react with the insulin receptor. Extracts were derived from cells
that were serum starved, stimulated with 10% serum, or
stimulated with both 10% serum and 50 ng/ml IGF-1 for 15
minutes. Consistent with the results from the phospho-RTK array
analysis, levels of phospho-IGF-1R did not correlate with R1507
sensitivity, regardless of cell culture conditions (Figure 2A).
Levels of total IGF-1R expression correlate with R1507
sensitivity
We next asked whether expression levels of total IGF-1R
correlated with R1507 sensitivity in NSCLC cells. Protein levels
were measured quantitatively by ELISA using an antibody specific
for both unphosphorylated and phosphorylated forms of the
protein (Figure 2B). Using a cutoff of 6000 picograms per 25
micrograms of total protein, 4 out of 5 sensitive cell lines displayed
high total IGF-1R levels, compared to 1 out of 17 resistant lines.
This difference was statistically significant (p=0.003, Fisher’s
Exact test).
We also interrogated IGF-1R gene copy number status in a
panel of NSCLC cell lines that were previously examined using
Affymetrix 250K SNP arrays. 4 and 12 of our sensitive and
resistant lines, respectively, happened to be included in the SNP
array analysis that was performed as part of a separate study [14].
Consistent with the data obtained from the ELISA experiments,
cell lines with copy number gain of IGF-1R were significantly
enriched for R1507-sensitive cell lines (p=0.002, Wilcoxon
rank sum test; Figure 3). We did not perform additional in situ
hybridization to confirm these findings. Notably, none of the 5
sensitive lines harbored any mutations in IGF-1R (data not shown).
IGF-1R signaling is necessary and sufficient for the
maintenance of AKT activation in sensitive cells
11–18 cells displayed the most sensitivity to R1507 (Figure 1).
Because they also harbor the L858R mutation of EGFR associated
with sensitivity to EGFR tyrosine kinase inhibitors like erlotinib
[16], we next investigated interactions between IGF-1R and
EGFR in the cells treated under various conditions. Cells were first
serum-starved overnight and then stimulated by addition of EGF,
IGF-1, or both. Additional cells were stimulated by both EGF and
IGF-1 but pre-treated with erlotinib, R1507, or both. As expected,
addition of EGF and IGF-1 induced robust phosphorylation of
EGFR and IGF-1R, respectively (Figure 4A–D). Pre-treatment
of cells with erlotinib abolished EGFR phosphorylation, while pre-
treatment with R1507 abolished phosphorylation of IGF-1R. The
latter was accompanied by degradation of total IGF-1R.
Ligand binding to IGF-1R and EGFR initiates a series of
phosphorylation events that can lead to activation of both the
MAPK pathway involved in cell proliferation and the PI3K/AKT
signaling pathway involved in cell survival [7]. Interestingly, in 11–
18 cells, AKT was activated by IGF-1 but not EGF stimulation.
Conversely, pre-treatment with R1507 but not erlotinib abolished
AKT phosphorylation (Figure 4A). These data indicate that the
IGF-1R pathway is both necessary and sufficient for AKT
activation in 11–18 cells. Similar results were obtained with
extracts from R1507-sensitive HCC15 cells treated in an
analogous manner (Figure 4B).
By contrast, R1507-resistant cell lines displayed different
signaling properties. For example, in H226 cells treated in an
analogous manner, both EGF and IGF-1 activated AKT, and
suppression of the IGF-1R pathway by R1507 alone was not
sufficient to eliminate AKT phosphorylation (Figure 4C).I n
HCC95 cells, AKT remained phosphorylated despite serum
starvation, and R1507 treatment could not abolish AKT
activation (Figure 4D). Similar results were obtained in R1507-
resistant PC-9 cells (data not shown). Collectively, these data
demonstrate that in R1507-sensitive cells, AKT is solely
dependent on IGF-1R for activation, whereas in R1507-resistant
cells, AKT can be activated by other pathways or remain
constitutively activated.
To verify further that AKT was required for IGF-1R signaling
in 11–18 cells, we examined the effect on AKT phosphorylation of
knocking down IGF-1R protein expression using gene-specific
short interfering RNAs (siRNAs) (Figure 4E). Consistent with
results obtained using R1507 treatment, IGF-1R siRNAs dramat-
ically decreased AKT phosphorylation without affecting ERK
phosphorylation in 11–18 cells. Cells treated with control siRNAs
against GAPDH did not display these changes.
Effects of R1507 co-treatment with erlotinib or paclitaxel
We examined the effects of adding erlotinib to R1507 on the
growth of 11–18 cells (Figure 5A). Compared to either single
agent alone, the combination further inhibited cell growth. Similar
results were obtained with the four other R1507 sensitive lines,
even though only 11–18 cells harbored a drug-sensitive EGFR
mutation. By contrast, there was no additive effect in adding
erlotinib to R1507 in the lines already resistant to R1507 alone.
We were unable to calculate a combination index for the drug
combination, as dose response curves derived from treatment of
cells with R1507 did not fit into a Hill-type of curve (Figure S2).
Analogous results were also obtained by combining R1507 with
the chemotherapeutic agent, paclitaxel (Figure S3).
We studied further in 11–18 cells the effect of the combination
of R1507 and erlotinib on inducing apoptosis, as measured by
standard annexin-V/propidium iodide (PI) assays. Although 11–
18 cells harbor a drug-sensitive EGFR L858R mutation, these cells
did not die after 24 h of exposure to erlotinib, even at a drug
concentration of 500 nanomolar (Figure 5B). Single agent
R1507 at 25 micrograms/milliliter had little effect as well.
However, co-treatment with both erlotinib and R1507 induced
an increase in annexin-V-positive cells, both at 100 nanomolar
(8.9% to 17.5%) and 500 nanomolar (8.9% to 25.4%) erlotinib
concentrations (p=0.007 and 0.0001, two sample t-test). Based
Anti-IGF-1R Therapy in NSCLC
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7273Figure 2. Total IGF-1R levels, but not phospho IGF-1R levels, are associated with R1507 sensitivity in NSCLC cells. A. Cell lines were
serum starved overnight, then stimulated with either 10% FBS, or 10% FBS plus 50 ng/ml IGF-1 for 15 minutes. Cell lysates were obtained for
phospho IGF-1R ELISA analysis. Y axis is expressed as absorbance at 450 nm, as no standard curve was available to calculate absolute amount. B. Cell
lines were serum starved overnight and lysates were obtained for total IGF-1R ELISA analysis. Cell lines are listed according to their relative sensitivity
to R1507.
doi:10.1371/journal.pone.0007273.g002
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contributes to apoptosis induction most likely by eliminating
survival-related AKT phosphorylation. Consistent with this
notion, we also observed enhanced apoptosis in 11–18 cells using
a combination of erlotinib and an experimental PI3K inhibitor
(data not shown).
IGF-1R expression in NSCLC tumors by IHC
Having identified total IGF-1R protein levels as a potential
biomarker of NSCLC cell line sensitivity to R1507, we sought an
independent, more clinically applicable assay to assess IGF-1R
status in human primary NSCLCs. We obtained a monoclonal
antibody (G11) that recognizes the C-terminus of both unpho-
sphorylated and phosphorylated forms of the IGF-1R beta chain.
The antibody does not cross react withthe insulin receptor (data not
shown). We then stained sections made from formalin-fixed
NSCLC cell lines and found a striking correlation between IHC
staining of the lines and levels of total IGF-1R as determined by
ELISAs (Figures 6A and 2B). Whereas sensitive lines with high
levels of total IGF-1R reacted strongly with G11 in a membranous
staining pattern, resistant lines with low levels of the protein did not.
We next performed IHC analysis on 4 existing tissue microarrays
(TMAs) comprised of primary NSCLC tumors from 270 patients.
Clinical characteristics of the patients are summarized in Table 1.
Receptor staining levels varied among tumor samples, from 0 to 3+
(Figure 6B and 6C, see methods for details). 39.3% of TMA
NSCLC tumors showed medium to high IGF-1R staining (scores of
2+ or 3+, respectively), while 16.7% tumors had 3+ scores. IGF-1R
expression was mostly localized to tumor cells showing partial to
complete strong membranous localization with weaker cytoplasmic
localization and tumor cell heterogeneity seen. Surrounding tissue
including fibroblasts and inflammatory cells such as lymphocytes
and plasma cells were negative, while normal lung alveoli, alveolar
macrophages and endothelial cells showed very weak, minimal to
negative cytoplasmic staining.
IGF-1R overexpression was strongly associated with squamous
cell carcinoma, as 79.2% of squamous cell lung cancer displayed
high IGF-1R staining versus 35.4% of adenocarcinomas
(p,0.0001, Table 1). There was no significant association
between IGF-1R expression levels with gender, smoking history
or age. Unlike smoking history or gender in this cohort of patients,
IGF-1R expression levels alone were not associated with survival
(Figure 6D and data not shown).
Discussion
A variety of strategies to target IGF-1R in cancers are now in
preclinical or clinical stages of development [4,5,6,17]. The two
main approaches involve anti-IGF-1R monoclonal antibodies and
small molecule inhibitors. Currently, there is a limited amount of
Figure 3. SNP array analysis of IGF-1R gene copy number status in a panel of NSCLC cell lines. Cell lines are listed from left to right
according to IGF-1R gene copy number, highest (red) to lowest (blue). See methods for details.
doi:10.1371/journal.pone.0007273.g003
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PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7273Figure 4. IGF-1R signaling is necessary and sufficient for the maintenance of AKT activation in sensitive cells. A–D. Cells were serum-
starved overnight and then stimulated with the indicated concentrations of EGF, IGF-1, or both for 15 minutes. Additional cells were pre-treated with
the indicated concentrations of erlotinib, R1507, or both for 3 hours. Cell lysates were analyzed by immunoblotting, using the indicated antibodies.t :
total protein; p: phospho-protein. E. 11–18 cells were transfected with siRNAs against the various indicated targets. 48 hours later, cells were
harvested, and lysates were analyzed by immunoblotting, using the indicated antibodies.
doi:10.1371/journal.pone.0007273.g004
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7273Figure 5. The combinatorial effect of R1507 and erlotinib in NSCLC cell lines. A. R1507 enhances erlotinib-induced growth inhibition in
R1507 sensitive cell lines. Various cell lines were treated with increasing concentrations of erlotinib in the absence or presence of 25 mg/ml R1507 for
72 hours and cell growth inhibition was measured by CellTiter Blue reagents. Data represent the mean 6 standard deviation of triplicates. B. The
combination of R1507 and erlotinib induced apoptosis in 11–18 cells. 11–18 cells were co-treated with 100 or 500 nM erlotinib in the absence or
presence of 25 mg/ml R1507 for 24 hours. The percentage of apoptotic cells (annexin V positive cells) was determined by annexin V/PI apoptosis
assays.
doi:10.1371/journal.pone.0007273.g005
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PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7273Figure 6. IGF-1R expression in primary NSCLC tissues. A. IGF-1R expression in NSCLC cells lines assessed by IHC analysis. IHC was performed
on paraffin-embedded NSCLC cell lines using the total IGF-1R antibody, G11 (see methods). Results were consistent with data obtained from total
IGF-1R ELISAs. B. IGF-1R expression in primary NSCLC tumors. IHC staining with G11 was performed on NSCLC tissue microarrays and scored as
follows: 0, no staining; 1, weak focal staining; 2, moderate staining; 3, strong staining with at least 10% of the core showing complete membranous
staining. Representative images are shown. C. Distribution of scores for total IGF-1R staining in primary NSCLCs. D. Kaplan-Meier curves for overall
survival in patients whose tumors scored 0 and 1+ versus 2+ to 3+.
doi:10.1371/journal.pone.0007273.g006
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therapy. In this study, through integrated analysis of 22 NSCLC
cell lines, we identified high expression levels of total IGF-1R as
one potential biomarker of sensitivity to R1507, an anti-IGF-1R
antibody. 4 out of 5 sensitive lines displayed high levels of total
IGF-1R versus 1 out of 17 resistant lines (p=0.003, Fisher’s
Exact). Consistent with this finding, others have recently reported
that drug-sensitive sarcomas also have high expression of total
IGF-1R [18].
By contrast, we did not find that levels of phospho-IGF-1R were
a predictive biomarker for R1507 sensitivity. Both R1507 sensitive
cells and resistant cells showed variable levels of phospho-IGF-1R,
regardless of culture conditions. This result may be due to the fact
that IGF-1R phosphorylation status is a dynamic process which
could have varied kinetic properties in different cell lines. We
collected samples uniformly 15 mins after ligand stimulation, but
peak IGF-1R phosphorylation following administration of IGF
could occur at variable times in different cells.
We screened 22 human NSCLC cell lines and identified only 5
lines with moderate response to R1507 single agent treatment in
vitro. Surprisingly, these ‘drug-sensitive’ NSCLC cell lines did not
undergo more than 25–50% growth inhibition or any significant
apoptosis when treated with R1507 alone. We only used one method
to assess such sensitivity (i.e. a growth inhibition assay). However, by
contrast, the growth of EGFR mutant cells that harbor drug-sensitive
EGFR kinase domain mutations is nearly completely blocked in this
same assay, and apoptosis is induced after analogous treatment with
gefitinib or erlotinib [13]. This result suggests that at least among the
drug-sensitive NSCLC cells we studied, IGF-1R activity alone is not
required for maintenance of the tumor cells in vitro. The receptor
does appear to contribute to cell survival, though. For example, 11–
18 cells, which harbor an erlotinib-sensitive EGFR mutation
(L858R), undergo only G1 arrest in response to erlotinib but undergo
apoptosis when co-treated with R1507 and erlotinib.
The lack of significant growth inhibition induced by R1507 in
NSCLC cells can be further explained by two additional factors.
First, IRs and IGF-1Rs can form hybrid receptors, and it is not yet
clear how specific anti-IGF-1R-targeted therapies will interfere
with signals emanating from hybrid receptors. However, use of
agents that target both IR and IGF-1R was not the focus of this
study. Second, we only assessed the effect of R1507 in vitro.
R1507 does not elicit antibody-dependent cytotoxicity, but the
antibody could still induce more dramatic responses in vivo.
Through analysis of EGFR, IGF-1R, and downstream MAPK
and AKT signaling pathways, we found in the R1507-sensitive
but not -resistant lines that IGF-1R activation is sufficient and
required for AKT activation. Activation of IGF-1R by IGF-1 or
inhibition of IGF-1R by R1507 had minimal effect on ERK
activation in either R1507 sensitive or resistant lines. Thus, IGF-
1R appears to be the major driving force for AKT activation in
drug-sensitive cells. The dependence of AKT on IGF-1R signaling
was further verified by knockdown of IGF-1R using siRNAs.
Consistent with this finding, previous studies have shown in
rhabdomyosarcoma cells that phospho-AKT status is controlled
predominantly by IGF-1R activation [18]. Insulin receptor
substrate 1 (IRS-1) is known to mediate the activation of PI3K
by associating with src homology 2 domains of p85 subunit of
PI3K upon IGF-1R pathway is activated [19]. In EGFR-
dependent cells, the activation of the PI3K/AKT pathway is
most likely via ERBB3 [20]. In future studies, it will be interesting
to examine the roles of IRS-1 and ERBB3 in mediating PI3K/
AKT activation in the R1507-sensitive and -resistant cells.
Through analysis of TMAs with another anti-IGF-1R antibody
(G11), we found evidence for high total IGF-1R expression in
primary human NSCLCs. 39.3% of tumors had medium to high
levels of IGF-1R expression (scores of 2+ to 3+), while 16.7% had
high IGF-1R expression (scored as 3+). Higher levels of expression
were associated with the squamous cell carcinoma subtype. There
was no correlation with gender, smoking history, or overall
survival. These results are consistent with a previous study with
fewer numbers of patients [21].
In a randomized phase II study of patients with advanced
treatment-naı ¨ve NSCLC, disease in those with squamous cell
carcinoma responded to the combination of paclitaxel, carboplatin
and an anti-IGF-1R antibody (CP-751,871) better than those with
other histological subtypes [22]. In our IHC studies (Table 1),a
majority of squamous cell lung cancers displayed high levels of
IGF-1R expression. These data suggest that squamous cell lung
cancers may be more sensitive than lung adenocarcinomas to IGF-
1R targeted therapy. However, in our growth inhibition assays,
only 1 out of 9 squamous cell carcinoma lines versus 4 out of 11
adenocarcinoma lines displayed moderate sensitivity to R1507.
This discrepancy could possibly be explained by phenotypic
changes that occur in squamous cell lines when they are grown in
vitro. Lung adenocarcinoma cell lines and primary tumors were
recently shown to be genetically and transcriptionally similar [14].
However, an analogous analysis has not yet been performed for
squamous cell lung cancer cell lines and primary tumors.
In summary, characterization of 22 NSCLC cell lines has lead
to identification of high expression levels of total IGF-1R as a
predictive marker of relative sensitivity to R1507, an anti-IGF-1R
antibody. In such sensitive cells but not resistant cells, additive
effects were observed by combining R1507 with other anti-cancer
agents. Immunohistochemical analysis of primary NSCLC tumors
with an anti-IGF-1R antibody demonstrated that a significant
fraction display high levels of the receptor. These results lay
groundwork for rationally designing clinical trials to enrich for
lung cancer patients that might benefit from treatment with anti-
IGF-1R antibodies like R1507.
Supporting Information
Figure S1 R1507 binds to human IGF-1R. 500 micrograms of
total protein from H3255 and 11–18 cell lysates were incubated
Table 1. Association of IGF-1R status with clinical variables.
Variable IGF-1R(2) IGF-1R(+)P
Histology Adeno 155 (64.6%) 85 (35.4%) ,0.0001
SCC 5 (20.8%) 19 (79.2%)
Sex F 78 (58.6%) 55 (41.4%) 0.58
M 62 (62.6%) 37 (37.4%)
Smoking Never 27 (62.8%) 16 (37.2%) 0.52
,15 pack/yr 18 (72%) 7 (28%)
$15 pack/yr 93 (59.6%) 63 (10.4%)
Age (mean) 69 610 (n=140) 68 610 (n=92) 0.25
Adeno – adenocarcinoma. SCC – squamous cell carcinoma. F – female. M – male.
Never smoker – smoked less than 100 cigarettes in a lifetime. Age is shown 6
standard deviation. Tumors with 2+ to 3+ staining levels were considered IGF-
1R(+), while tumors with 0 to 1+ levels were considered IGF-1R(-). Fisher’s exact
test was performed to analyze the association of IGF-1R with histology, sex, and
smokinghistory.Two-samplet-test wasperformedto evaluateIGF-1R association
with age.
Note: the numbers do not add up to 270 because not all clinical variables were
available for all samples examined.
doi:10.1371/journal.pone.0007273.t001
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protein A/G beads (Santa Cruz Biotechnology). Immunoprecip-
itates (IP) were separated by SDS/PAGE and then subjected to
immunoblotting with a commercial antibody against the beta
chain of IGF-1R. WCL - whole cell lysates.
Found at: doi:10.1371/journal.pone.0007273.s001 (0.93 MB TIF)
Figure S2 The single agent activity of R1507 in sensitive lines.
Various cell lines were treated with R1507 for 72 hours, and
growth inhibition was measured using CellTiter Blue reagents.
Found at: doi:10.1371/journal.pone.0007273.s002 (0.72 MB TIF)
Figure S3 The combinatorial effect of R1507 and paclitaxel in
NSCLC cell lines. R1507 enhances paclitaxel-induced growth
inhibition in R1507 sensitive cell lines. Various cell lines were
treatedwithincreasingconcentrationsofpaclitaxelintheabsenceor
presence of 25 mg/ml R1507 for 72 hours, and growth inhibition
was measured by CellTiter Blue reagents. Data represent the mean
6 standard deviation of triplicates.
Found at: doi:10.1371/journal.pone.0007273.s003 (0.23 MB TIF)
Table S1 IGF-1R cDNA sequencing primers.
Found at: doi:10.1371/journal.pone.0007273.s004 (0.06 MB
PDF)
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